Zydus Lifesciences will roll out generic semaglutide injections in India post-patent expiry, using a reusable single-pen ...

India’s market for anti-obesity medicines is expected to undergo a significant shift in 2026, with prices of leading ...

Zydus plans to launch its diabetes and obesity injection using a reusable adjustable pen device after patent expiry, as more Indian drugmakers enter the market.

CLEVELAND, Ohio — Patients with Type 1 diabetes have lost the specialized pancreatic cells that produce insulin, putting them ...

Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...

Novo Nordisk will cut prices of the diabetes and weight loss drugs Ozempic, Rybelsus and Wegovy to $675 effective Jan. 1, 2027.

Daily orforglipron tablets led to greater weight loss than semaglutide tablets, offering potential oral alternative to Wegovy and Mounjaro ...

Weight loss medications Mounjaro and Zepbound, which contain the active ingredient tirzepatide, may lower the risk of ...

An innovative insulin implant could redefine the future of diabetes management. Here's how this breakthrough diabetes treatment works, its benefits, risks, and what it means for people living with ...

Experts have hailed a powerful new weapon in the fight against Type 2 diabetes – a simple daily pill that can help people shed pounds and bring their blood sugar levels under control. Orfroglipron, ...

The price of the popular GLP-1 medications will be cut, starting in January of 2027, manufacturer Novo Nordisk said in a ...

Zydus to launch Semaglutide Injection in India, featuring a unique reusable pen for improved diabetes and obesity management.